On February 26, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, reported its participation in various upcoming industry conferences (Press release, Immutep, FEB 26, 2019, View Source [SID1234533730]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company will be presenting updated clinical data from the Phase I TACTI-mel trial in metastatic melanoma for its lead product candidate eftilagimod alpha ("efti" or "IMP321") and new data relating to its pre-clinical product candidate, IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases, at industry conferences in March 2019.
Conference:
World Immunotherapy Congress USA 2019
Dates:
3-5 March 2019
Venue:
Grand Hyatt, San Diego, USA
Presentation Title:
Two ACTive Immunotherapies (TACTI): Results of a Phase I trial with metastatic melanoma patients
Presenter:
Dr. Frédéric Triebel, CSO and CMO of Immutep
Conference:
14th Congress of ECCO (European Crohn’s and Colitis Organisation)
Dates:
6-9 March 2019
Venue:
Bella Center, Copenhagen, Denmark
Presentation Title:
IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases
Presenter:
Mathieu Angin, Phd, Immutep Research Scientist